FOLH1 and prostate carcinoma: 177Lu vipivotide tetraxetan has been approved for PSMA-positive, metastatic, and castration-resistant prostate cancer in patients previously treated with androgen receptor inhibitors and taxane drugs (Aschenbrenner 2022).